Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Podsiadlik who wrote (81000)	10/14/2002 8:30:34 AM
From: StockDung	Respond to of 122087

Taglich Brothers Updated Research Report On Hemispherx Raises Target Price From $13.75 to $25.00 With a Discounted Present Value of $21.08 PHILADELPHIA--(BUSINESS WIRE)--Sept. 30, 2002-- Recommendation Changed to Buy from Speculative Buy; Analyst Andre Garnet Projects Post Approval First Year Revenue's at $160 Million Hemispherx Biopharma, Inc. (AMEX:HEB), a leading company in the experimental stage development of immune based therapies primarily addressing the diseases of HIV AIDS and Chronic Fatigue Syndrome, announced today the issuance of the following research report update by Taglich Brothers senior biotech analyst Andre Garnet. The full text of the report is available on the Taglich Brothers Website at www.taglichbrothers.com Highlights of the report reveal the following: - Recommendation raised to buy from speculative buy - The target price has been raised from $13.75 to $25.00 - First year revenue after FDA approval for Ampligen's indications in HIV/AIDS and Chronic Fatigue Syndrome (CFS) are projected at $160 million. This is based on a market penetration of only 0.5%, which Mr. Garnet indicates maybe to conservative and consequently revenues could be significantly higher. - The report expresses the belief that Ampligen has more than a 90% probability of obtaining FDA and European regulatory approval for both CFS and HIV/AIDS. Mr. Garnet wrote the report in conjunction with Laura Conroy. Mr. Garnet has covered the Biotech Industry for over 10 years and has a strong track record for discovering undervalued small cap companies within the industry. About Hemispherx Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information, including the full text of the abstract described in this press release, please visit the company's Web site at www.hemispherx.net Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. CONTACT: Hemispherx Biopharma, Inc. Investor Relations: 215/988-1712 Fax: 215/988-1554 ir@hemispherx.net Website: www.hemispherx.net or MRB Investor Relations, LLC Wesley Stanton, 212/495-0200, ext. 11 Fax: 212/495-0746 wstanton@mrb-ir.com or Dianne Will, 518/399-6222 dwill@willstar.net SOURCE: Hemispherx Biopharma, Inc. Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: businesswire.com 09/30/2002 09:09 EASTERN